Esther Weidberg
Rockville Centre, NYNPI 1346888484
Payments from drug & device makers
Across 116 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$428
- Antares Pharma, Inc.$248
- Bayer$242
- Lilly USA, LLC$203
- Novo Nordisk$189
- Ardelyx, Inc.$99
- plus $990 from 25 others
What the payments were for
- Food & beverage$2,37899%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $428 |
| Antares Pharma, Inc. | 12 | $248 |
| Bayer | 10 | $242 |
| Lilly USA, LLC | 10 | $203 |
| Novo Nordisk | 9 | $189 |
| Ardelyx, Inc. | 4 | $99 |
| GSK | 5 | $84 |
| Alkermes, Inc. | 4 | $78 |
| Indivior Inc. | 4 | $75 |
| Merck | 3 | $70 |
| Halozyme Inc | 3 | $67 |
| Amgen | 3 | $62 |
| Intra-sana Laboratories | 3 | $59 |
| Medicomp Inc | 2 | $56 |
| Medtronic | 2 | $48 |
| Hologic Sales And Service, LLC | 1 | $44 |
| Corcept Therapeutics | 2 | $43 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| AstraZeneca | 2 | $31 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Renalytix AI, Inc. | 1 | $20 |
| Resmed Corp | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Bausch Health US, LLC | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Corium, LLC | 2 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 21 | $396 |
| Atorvastatin Calcium | 45 | $339 |
| Losartan Potassium | 30 | $285 |
| Omeprazole | 18 | $199 |
| Metoprolol Succinate | 14 | $154 |
| Fluticasone Propionate | 14 | $147 |
| Levothyroxine Sodium | 12 | $143 |
| Simvastatin | 18 | $141 |
| Hydrochlorothiazide | 13 | $79 |
| Trazodone Hcl | 13 | $59 |
| Metformin Hcl | 20 | $57 |
| Amlodipine Besylate | 20 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $24 | $14312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.